Pharmabcine Inc.

Korea Research Institute of Bioscience and Biotechnology

Jin-San Yoo

Sung-Woo Kim

Do-Yun Kim

Chae-Ok Yun

Semi Kim

Weon Sup Lee

Young-Guen Kwon

Sang Soon Byun

Nahm-Ju Kim

Dong-Heon Lee

Too-Hyon Cho

Sam-Sook Sul

Bo-Jeong Pyun

Kwi-Hwa Kim

Sang-Seok Koh

Geun-Bae Rha

Hyeon-Mi Yoo

Jae-Won Jeon

Dong-Sup Lee

Young-Woo Park

Hyun-Sook Jang

Jeong-Eun Kang

Weon-Sup Lee

Sang-Ryeol Shim

Mi-Hee Park

Eun Hee Lee

Miju Park

Jinsang Yoo

Youngae Lee

Sungho Ahn

Do-yun Kim

Keunhee Oh

Joon-Chul Lee

Hyuk Jin Lee

Jae Bong Yoon

Sang Ryeol Shim

Seon-Young Lee

Jinhee Choi

Mi-Ra Lee

Joon Chul Lee

Young Kyu Park

Hee Young Kang

Se-mi Kim

Shin Ae Yi

Hyuk Joon Lee

Jung Min Ha

Myoung Suk Choi

Mi Ju Park

Disclosed are an anti-PD-L1 antibody or an antigen-binding fragment thereof, a nucleic acid encoding the same, a vector including the nucleic acid, a cell transformed with the vector, a method for producing the antibody or an antigen-binding fragment thereof, a pharmaceutical composition for preventing or treating cancer containing the same, and a composition for co-administration with an antibody other than an antibody binding to PD-L1, containing the same.

Anti-PD-L1 antibody and use thereof

The present invention relates to an anti-VISTA antibody or an antigen binding fragment thereof, a nucleic acid coding for the same, a vector carrying the nucleic acid, a cell transformed with the vector, a method for preparing the antibody or an antigen binding fragment thereof, a composition for prevention or treatment of autoimmune disease, comprising the same antibody, and a composition for concurrent administration in combination with a PD-1 antibody or PD-L1 antibody.

Anti-VISTA antibody and use thereof

The present disclosure relates to an antibody specifically binding to epidermal growth factor receptor variant III (EGFRvIII), to nucleic acid coding the antibody, to a vector comprising the nucleic acid, to a host cell, to a preparation method of the antibody, and to a pharmaceutical composition comprising the antibody as an active ingredient for treating a cancer or a tumor.

EGFRvIII antibody and composition comprising same

The present invention relates to a method for screening anticancer agent or SIP1/ZEB2 inhibitor using integrin alpha 5 (ITGA5), more precisely a method for measuring integrin alpha 5 expression pattern in SIP1/ZEB2 over-expressing cell line or SIP1/ZEB2 expression induced cell line, both treated with sample compounds, by comparing with that of the control. The method of the present invention facilitates screening of anticancer agent or SIP1/ZEB2 inhibitor simply by measuring integrin alpha 5 expression, so that it can be effectively applied in the field of medicine.

Method for screening anticancer agent or SIP1/ZEB2 inhibitor using integrin alpha 5

The present invention relates to human monoclonal antibodies neutralizing vascular endothelial growth factor receptor and the use thereof. More specifically, relates to human ScFv molecules neutralizing vascular endothelial growth factor receptor, and a composition for inhibiting angiogenesis and a composition for treating cancer, which contain the human ScFv molecules. The disclosed monoclonal antibody neutralizing vascular endothelial growth factor receptor shows excellent neutralizing ability in living cells, compared to that of a commercially available antibody against vascular endothelial growth factor receptor, and shows the ability to neutralize vascular endothelial growth factor receptor not only in humans, but also in mice and rats. Thus, the monoclonal antibody will be useful in anticancer studies and will be highly effective in cancer treatment.

Human monoclonal antibody neutralizing vascular endothelial growth factor receptor and use thereof

Growing community of inventors

Daejeon, South Korea

Jin-San Yoo